NO20071592L - GLP-1 og exendinrelatert oppfinnelse - Google Patents

GLP-1 og exendinrelatert oppfinnelse

Info

Publication number: NO20071592L
Authority: NO; Norway
Prior art keywords: glu; ser; gly; leu; ala
Prior art date: 2004-09-03

Application number

NO20071592A

Other languages

English (en)

Norwegian (no)

Inventor

Martin Gotthardt

Martin Behe

Thomas Behr

Burkhard J Goke

Original Assignee

Univ Marburg Philipps

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-09-03

Filing date

2007-03-27

Publication date

2007-05-29

2007-03-27 Application filed by Univ Marburg Philipps filed Critical Univ Marburg Philipps

2007-05-29 Publication of NO20071592L publication Critical patent/NO20071592L/no

Links

DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 2
102100025101 GATA-type zinc finger protein 1 Human genes 0.000 title 1
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 title 1
102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 abstract 2
108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 2
JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 abstract 2
LMHMJYMCGJNXRS-IOPUOMRJSA-N exendin-3 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 LMHMJYMCGJNXRS-IOPUOMRJSA-N 0.000 abstract 2
108010011459 Exenatide Proteins 0.000 abstract 1
150000001412 amines Chemical class 0.000 abstract 1
108091006116 chimeric peptides Proteins 0.000 abstract 1
239000000824 cytostatic agent Substances 0.000 abstract 1
230000001085 cytostatic effect Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
229960001519 exenatide Drugs 0.000 abstract 1
108010015174 exendin 3 Proteins 0.000 abstract 1
239000003446 ligand Substances 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Toxicology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Physics & Mathematics (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Vascular Medicine (AREA)
Cell Biology (AREA)
Pathology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Optics & Photonics (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Analytical Chemistry (AREA)

NO20071592A 2004-09-03 2007-03-27 GLP-1 og exendinrelatert oppfinnelse NO20071592L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE102004043153A DE102004043153B4 (de)	2004-09-03	2004-09-03	Erfindung betreffend GLP-1 und Exendin
PCT/DE2005/001503 WO2006024275A2 (de)	2004-09-03	2005-08-26	Erfindung betreffend glp-1 und exendin

Publications (1)

Publication Number	Publication Date
NO20071592L true NO20071592L (no)	2007-05-29

Family

ID=35970651

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20071592A NO20071592L (no)	2004-09-03	2007-03-27	GLP-1 og exendinrelatert oppfinnelse

Country Status (16)

Country	Link
US (2)	US8268781B2 (pl)
EP (3)	EP2301962B1 (pl)
JP (1)	JP5047795B2 (pl)
KR (1)	KR101237152B1 (pl)
CN (3)	CN102358752B (pl)
AT (1)	ATE486090T1 (pl)
AU (1)	AU2005279537C1 (pl)
BR (1)	BRPI0515624A (pl)
CA (2)	CA2578252A1 (pl)
DE (2)	DE102004043153B4 (pl)
HR (1)	HRP20110061T1 (pl)
MX (1)	MX2007002455A (pl)
NO (1)	NO20071592L (pl)
PL (2)	PL2070946T3 (pl)
RU (3)	RU2489443C2 (pl)
WO (1)	WO2006024275A2 (pl)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2007017892A2 (en) *	2005-05-05	2007-02-15	Cadila Healthcare Limited	Novel compounds as glp-i agonists
EP3456340B1 (en)	2007-01-08	2022-02-16	The Trustees of the University of Pennsylvania	Glp-1 receptor antagonist for use in the treatment of congenital hyperinsulinism
JP4642920B2 (ja) *	2008-09-20	2011-03-02	国立大学法人京都大学	膵島イメージング用分子プローブ前駆体及びその使用
PT3228320T (pt)	2008-10-17	2020-03-26	Sanofi Aventis Deutschland	Combinação de uma insulina e de um agonista do glp-1
WO2010118034A2 (en) *	2009-04-06	2010-10-14	Board Of Regents, The University Of Texas System	Cyclic peptide analogues for non-invasive imaging of pancreatic beta-cells
WO2011019020A1 (ja) *	2009-08-10	2011-02-17	国立大学法人京都大学	膵島イメージング用分子プローブ及びその前駆体、並びに、それらの使用
WO2011027584A1 (ja) *	2009-09-04	2011-03-10	国立大学法人京都大学	膵島イメージング用分子プローブ及びその使用
JP5608867B2 (ja) *	2009-09-30	2014-10-15	国立大学法人京都大学	膵島イメージング用分子プローブ及びその使用
JP5832439B2 (ja)	2009-11-13	2015-12-16	サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物
SG10201500871TA (en)	2009-11-13	2015-04-29	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a glp-1 agonist and methionine
KR101550006B1 (ko)	2009-12-10	2015-09-03	아크레이 가부시키가이샤	췌도 이미징용 분자 프로브 및 그 사용
CN101875700B (zh) *	2010-04-09	2012-09-26	无锡和邦生物科技有限公司	一种增加促胰岛素分泌肽融合蛋白生物活性的方法
CN103179978A (zh)	2010-08-30	2013-06-26	赛诺菲-安万特德国有限公司	Ave0010用于制造供治疗2型糖尿病用的药物的用途
US9278146B2 (en)	2010-10-08	2016-03-08	Kyoto University	Peptide derivative and use of the same
WO2012121746A2 (en) *	2011-03-09	2012-09-13	The General Hospital Corporation	Imaging beta cell mass
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2013004983A1 (en)	2011-07-04	2013-01-10	Imperial Innovations Limited	Novel compounds and their effects on feeding behaviour
JP6367115B2 (ja)	2011-08-29	2018-08-01	サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	２型糖尿病患者の血糖コントロールに使用する組合せ医薬
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US8901484B2 (en) *	2012-04-27	2014-12-02	Sanofi-Aventis Deutschland Gmbh	Quantification of impurities for release testing of peptide products
WO2013182217A1 (en) *	2012-04-27	2013-12-12	Sanofi-Aventis Deutschland Gmbh	Quantification of impurities for release testing of peptide products
UA116217C2 (uk)	2012-10-09	2018-02-26	Санофі	Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI617574B (zh) *	2012-12-11	2018-03-11	梅迪繆思有限公司	用於治療肥胖之升糖素與ｇｌｐ－１共促效劑
HUE035803T2 (en)	2012-12-21	2018-05-28	Sanofi Sa	Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
CN103344764B (zh) *	2013-06-19	2014-11-26	天津美德太平洋科技有限公司	胰高血糖素样肽-1生物学活性检测试剂及检测方法和试剂盒
WO2015086730A1 (en)	2013-12-13	2015-06-18	Sanofi	Non-acylated exendin-4 peptide analogues
TW201609797A (zh)	2013-12-13	2016-03-16	賽諾菲公司	雙重ｇｌｐ－１／升糖素受體促效劑
EP3080154B1 (en)	2013-12-13	2018-02-07	Sanofi	Dual glp-1/gip receptor agonists
WO2015086728A1 (en)	2013-12-13	2015-06-18	Sanofi	Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625669A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh)	2014-04-07	2016-07-16	賽諾菲公司	作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh)	2014-04-07	2016-07-16	賽諾菲公司	衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
US11311519B2 (en)	2014-05-01	2022-04-26	Eiger Biopharmaceuticals, Inc.	Treatment of hepatitis delta virus infection
US9932381B2 (en)	2014-06-18	2018-04-03	Sanofi	Exendin-4 derivatives as selective glucagon receptor agonists
DE102014112747A1 (de) *	2014-09-04	2016-03-10	Eberhard Karls Universität Tübingen Medizinische Fakultät	Verwendung eines Quinoxalinderivats in einem bildgebenden Verfahren
CN107206058A (zh)	2014-12-12	2017-09-26	赛诺菲-安万特德国有限公司	甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
PL3297654T3 (pl)	2015-05-22	2021-12-20	The Board Of Trustees Of The Leland Stanford Junior University	Leczenie pobariatrycznej hipoglikemii eksendyną (9-39)
AR105319A1 (es)	2015-06-05	2017-09-27	Sanofi Sa	Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh)	2015-07-10	2017-02-16	賽諾菲公司	作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
SI3389697T1 (sl)	2015-12-14	2021-02-26	Antaros Medical Ab	Selektivni agonisti receptorja glukagona, ki obsegajo kelatni del za namene prikazovanja
WO2017152014A1 (en)	2016-03-04	2017-09-08	Eiger Biopharmaceuticals, Inc.	Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives
SMT202500120T1 (it)	2016-11-21	2025-05-12	Amylyx Pharmaceuticals Inc	Formulazioni tamponate di esendina (9-39)
EP4171662A1 (en)	2020-03-31	2023-05-03	Antaros Medical AB	Selective gip receptor agonists comprising a chelating moiety for imaging and therapy purposes

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE120374T1 (de) *	1989-07-20	1995-04-15	Sandoz Ag	Markierte polypeptidderivate.
US5424286A (en) *	1993-05-24	1995-06-13	Eng; John	Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5705483A (en) *	1993-12-09	1998-01-06	Eli Lilly And Company	Glucagon-like insulinotropic peptides, compositions and methods
US5574008A (en) *	1994-08-30	1996-11-12	Eli Lilly And Company	Biologically active fragments of glucagon-like insulinotropic peptide
AU723694B2 (en) *	1996-06-05	2000-08-31	Roche Diagnostics Gmbh	Exendin analogues, processes for their preparation and medicaments containing them
JP2002508162A (ja) *	1998-02-27	2002-03-19	ノボノルディスクアクティーゼルスカブ	Ｎ末端を短縮したｇｌｐ−１誘導体
AU3247799A (en) *	1998-02-27	1999-09-15	Novo Nordisk A/S	Glp-1 derivatives of glp-1 and exendin with protracted profile of action
US7259136B2 (en) *	1999-04-30	2007-08-21	Amylin Pharmaceuticals, Inc.	Compositions and methods for treating peripheral vascular disease
EP1137667B1 (en) *	1998-12-07	2004-11-17	Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S.	Analogues of glp-1
BR0010705A (pt) *	1999-04-30	2002-02-05	Amylin Pharmaceuticals Inc	Exendinas modificadas e agonistas da exendina
AU765753B2 (en) *	1999-05-17	2003-09-25	Conjuchem Biotechnologies Inc.	Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
PT1180121E (pt) *	1999-05-17	2004-03-31	Conjuchem Inc	Peptidos insulinotropicos de longa duracao
US6528486B1 (en) *	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
EP1076066A1 (en) *	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels
WO2001051078A1 (en) *	2000-01-10	2001-07-19	Amylin Pharmaceuticals, Inc.	Use of exendins and agonists thereof for modulation of triglyceride levels and treatment of dyslipidemia
US7514078B2 (en) *	2001-06-01	2009-04-07	Cornell Research Foundation, Inc.	Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
US20030232761A1 (en) *	2002-03-28	2003-12-18	Hinke Simon A.	Novel analogues of glucose-dependent insulinotropic polypeptide
BR0314996A (pt) *	2002-10-02	2005-08-09	Zealand Pharma As	Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
WO2004037859A1 (ja) *	2002-10-11	2004-05-06	Sanwa Kagaku Kenkyusho Co., Ltd.	Glp-1誘導体及びその経粘膜吸収型製剤

2004
- 2004-09-03 DE DE102004043153A patent/DE102004043153B4/de not_active Expired - Fee Related
2005
- 2005-08-26 RU RU2010148447/10A patent/RU2489443C2/ru not_active IP Right Cessation
- 2005-08-26 CN CN201110114845.XA patent/CN102358752B/zh not_active Expired - Fee Related
- 2005-08-26 KR KR1020077007577A patent/KR101237152B1/ko not_active Expired - Fee Related
- 2005-08-26 DE DE502005010449T patent/DE502005010449D1/de not_active Expired - Lifetime
- 2005-08-26 PL PL08020703T patent/PL2070946T3/pl unknown
- 2005-08-26 WO PCT/DE2005/001503 patent/WO2006024275A2/de not_active Ceased
- 2005-08-26 EP EP10012756.2A patent/EP2301962B1/de not_active Expired - Lifetime
- 2005-08-26 HR HR20110061T patent/HRP20110061T1/hr unknown
- 2005-08-26 RU RU2007112115/10A patent/RU2420536C2/ru not_active IP Right Cessation
- 2005-08-26 JP JP2007528593A patent/JP5047795B2/ja not_active Expired - Fee Related
- 2005-08-26 AT AT05778889T patent/ATE486090T1/de active
- 2005-08-26 AU AU2005279537A patent/AU2005279537C1/en not_active Ceased
- 2005-08-26 CN CN2011101471272A patent/CN102304179A/zh active Pending
- 2005-08-26 CN CN2005800297604A patent/CN101010340B/zh not_active Expired - Fee Related
- 2005-08-26 BR BRPI0515624-6A patent/BRPI0515624A/pt not_active IP Right Cessation
- 2005-08-26 CA CA002578252A patent/CA2578252A1/en not_active Abandoned
- 2005-08-26 EP EP08020703.8A patent/EP2070946B1/de not_active Expired - Lifetime
- 2005-08-26 CA CA2797666A patent/CA2797666A1/en not_active Abandoned
- 2005-08-26 EP EP05778889A patent/EP1784422B1/de not_active Expired - Lifetime
- 2005-08-26 MX MX2007002455A patent/MX2007002455A/es active IP Right Grant
- 2005-08-26 PL PL10012756T patent/PL2301962T3/pl unknown
2007
- 2007-03-02 US US11/712,978 patent/US8268781B2/en not_active Expired - Fee Related
- 2007-03-27 NO NO20071592A patent/NO20071592L/no not_active Application Discontinuation
2010
- 2010-11-26 RU RU2010148446/10A patent/RU2486197C2/ru not_active IP Right Cessation
2012
- 2012-08-24 US US13/593,866 patent/US20130095037A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PL2301962T3 (pl)	2014-05-30
WO2006024275A3 (de)	2006-11-30
KR20070093960A (ko)	2007-09-19
US20130095037A1 (en)	2013-04-18
EP2301962B1 (de)	2013-10-30
DE502005010449D1 (de)	2010-12-09
HRP20110061T1 (hr)	2011-02-28
US20090180953A1 (en)	2009-07-16
BRPI0515624A (pt)	2008-07-29
EP2070946A3 (de)	2009-09-09
EP2070946B1 (de)	2013-05-29
WO2006024275A2 (de)	2006-03-09
MX2007002455A (es)	2007-10-10
AU2005279537A1 (en)	2006-03-09
ATE486090T1 (de)	2010-11-15
RU2007112115A (ru)	2008-10-10
JP2008511557A (ja)	2008-04-17
US8268781B2 (en)	2012-09-18
KR101237152B1 (ko)	2013-03-04
JP5047795B2 (ja)	2012-10-10
RU2010148447A (ru)	2012-06-10
EP2301962A3 (de)	2011-11-02
AU2005279537C1 (en)	2012-07-05
RU2486197C2 (ru)	2013-06-27
RU2420536C2 (ru)	2011-06-10
RU2010148446A (ru)	2012-06-10
AU2005279537B2 (en)	2012-02-16
DE102004043153A1 (de)	2006-03-23
RU2489443C2 (ru)	2013-08-10
CN102358752A (zh)	2012-02-22
EP2070946A2 (de)	2009-06-17
DE102004043153B4 (de)	2013-11-21
CA2797666A1 (en)	2006-03-09
EP1784422A2 (de)	2007-05-16
CN101010340B (zh)	2012-11-28
CN101010340A (zh)	2007-08-01
CN102304179A (zh)	2012-01-04
EP1784422B1 (de)	2010-10-27
CA2578252A1 (en)	2006-03-09
PL2070946T3 (pl)	2013-09-30
EP2301962A2 (de)	2011-03-30
CN102358752B (zh)	2014-07-30

Legal Events

Date	Code	Title	Description
2016-03-29	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
DE502005010449D1 (de)	2010-12-09	Erfindung betreffend glp-1 und exendin
JOP20210337A1 (ar)	2023-01-30	مواد مساعدة لمستقبل الببتيد الشبيه بالجلوكاجون 1
AR131857A2 (es)	2025-05-07	Compuestos co-agonistas de gip y glp-1
JOP20230077A1 (ar)	2023-04-16	محفزات glp 1/ gip مزدوجة
JOP20210016A1 (ar)	2021-01-21	مركبات مساعدة مشتركة gip/glp1
PA8738401A1 (es)	2009-02-09	Proteinas de fusion de exendina
RU2010101232A (ru)	2011-07-27	Производное инсулинотропного пептида, содержащее модифицированную n-концевую аминокислоту
DK1761553T3 (da)	2010-02-01	MHC molecule-binding tumor-associated peptides
EA200800699A1 (ru)	2008-10-30	Слитые полипептиды, содержащие glp-1 (глюкагонподобный пептид-1), с повышенной устойчивостью к пептидазам
DK1171465T3 (da)	2004-12-13	Analoger til gastroinhibitorisk peptid og deres anvendelse til behandling af diabetes
PE20231842A1 (es)	2023-11-21	Coagonistas de los receptores de glp-1 y gip
EA200100289A1 (ru)	2001-10-22	Способ введения инсулинотропных пептидов
HRP20020996B1 (hr)	2011-09-30	Analozi peptida-1 nalik na glukagon
EA200700391A1 (ru)	2007-10-26	Комбинированное лечение с применением слитых белков трансферрина, содержащих glp-1
NO20063436L (no)	2006-08-25	Intranasal administrasjon av glukose-regulerende peptider
WO2003058203A3 (en)	2007-02-01	Extended glucagon-like peptide-1 analogs
EA200300644A1 (ru)	2003-12-25	Слитые белки glp-1
WO2008033395A3 (en)	2008-05-15	Melanocortin and transferrin fusion proteins
MX2025005440A (es)	2025-06-02	Agonistas del receptor del peptido-1 similar al glucagon
CR20250178A (es)	2025-06-06	Agonistas del receptor del péptido-1 similar al glucagón
NO20080552L (no)	2008-03-27	GLP-1 farmasoytiske sammensetninger
Karas et al.	2013	Total chemical synthesis of a heterodimeric interchain bis‐lactam‐linked peptide: application to an analogue of human insulin‐like peptide 3
NO20051938L (no)	2005-04-20	Promoter til IL-18BP, dens fremstilling og anvendelse
TH2101000319A (th)	2025-06-30	สารประกอบอะโกนิสท์ร่วม gip/glp1
AR060795A1 (es)	2008-07-16	Moleculas quimericas fusionadas a matrilina 1, de uso terapeutico